

Richter and Palatin terminate license agreement of Bremelanotide

Budapest (Hungary) – 21 September 2015 – Gedeon Richter Plc. announces that the license and collaboration agreement established with the US based Palatin Technologies in September 2014, to co-develop and commercialize bremelanotide for female sexual dysfunction (FSD) indications in the European Union, other European countries and additional selected countries was terminated under mutually agreed terms fully releasing the parties from any and all legal and financial claims or obligations.

Notwithstanding the above decision, becoming a global player in Female Healthcare franchise remains a paramount strategic objective for the Company.

About Gedeon Richter

Gedeon Richter Plc. (www.richter.hu), headquartered in Budapest/Hungary, is a major pharmaceutical company in Central Eastern Europe, with an expanding direct presence in Western Europe. Richter's consolidated sales were approximately EUR 1.1 billion (US\$ 1.5 billion), while its market capitalization amounted to EUR 2.1 billion (US\$ 2.5 billion) in 2014. The product portfolio of Richter covers almost all important therapeutic areas, including gynaecology, central nervous system, and cardiovascular areas. Having the largest R&D unit in Central Eastern Europe, Richter's original research activity focuses on CNS disorders. With its widely acknowledged steroid chemistry expertise, Richter is a significant player in the female healthcare field worldwide. Richter is also active in biosimilar product development.

For more information:

Investors: Katalin Ördög: +36 1 431 5680

Media: Zsuzsa Beke: +36 1 431 4888